Granata, Riccarda https://orcid.org/0000-0003-4164-7313
Leone, Sheila
Zhang, Xianyang
Gesmundo, Iacopo
Steenblock, Charlotte https://orcid.org/0000-0002-9635-4860
Cai, Renzhi
Sha, Wei https://orcid.org/0000-0003-4740-2325
Ghigo, Ezio
Hare, Joshua M. https://orcid.org/0000-0002-7751-5032
Bornstein, Stefan R. https://orcid.org/0000-0002-5211-2536
Schally, Andrew V.
Article History
Accepted: 15 October 2024
First Online: 13 November 2024
Change Date: 16 December 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41574-024-01081-w
Change Date: 28 November 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41574-024-01069-6
Competing interests
: A.V.S., R.C., X.Z., W.S. and J.M.H. are co-inventors on the patents for GHRH analogues assigned to the University of Miami and Veterans Affairs Medical Center. J.M.H. reports having a patent for cardiac cell-based therapy and holds equity in Vestion Inc. and maintains a professional relationship with Vestion Inc. as a consultant and member of the Board of Directors and Scientific Advisory Board. Vestion Inc. did not play a role in the preparation or funding of the article. J.M.H. is the Chief Scientific Officer, a compensated consultant and board member for Longeveron Inc. and holds equity in Longeveron. J.M.H. is also the co-inventor of intellectual property licensed to Longeveron. Longeveron did not play a role in the preparation or funding of this article. The University of Miami is an equity owner in Longeveron Inc., which has licensed intellectual property from the University of Miami. The other authors declare no competing interests.